Dermatol. praxi. 2026;20(2):84-86 | DOI: 10.36290/der.2026.015

The fractional 1927-nm thulium laser as a treatment modality for actinic keratosis

MUDr. Kevin Machů
Dermamedest s. r. o., Praha
Aesthescar s. r. o., Praha
Oblastní nemocnice Kladno, a. s.

This paper presents a case report of a 45-year-old patient in whom multiple actinic keratoses of the scalp consistent with field cancerization were detected during a total body dermoscopic examination. At the same time, a nodular basal cell carcinoma on the right shoulder was identified. Considering the patient's preferences, treatment with a 1927 nm fractional thulium laser was chosen. The first session was well tolerated by the patient and led to a marked improvement in both clinical and dermoscopic findings. The article further discusses the use of the fractional thulium laser in the treatment of actinic keratoses and its role among other therapeutic approaches.

Keywords: actinic keratosis, field cancerization, fractional thulium (1927 nm) laser, laser therapy.

Accepted: June 8, 2026; Published: June 18, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Machů K. The fractional 1927-nm thulium laser as a treatment modality for actinic keratosis. Dermatol. praxi. 2026;20(2):84-86. doi: 10.36290/der.2026.015.
Download citation

References

  1. Marques E, Chen TM. Actinic Keratosis. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557401/.
  2. Rstom S, Abdalla B, Blumetti T, et al. Dermoscopy and Reflectance Confocal Microscopy in Actinic Keratosis, Intraepithelial Carcinoma, and Invasive Squamous Cell Carcinoma. J Drugs Dermatol. 2022 Mar 1;21(3):259-268. doi: 10.36849/JDD.5086. PMID: 35254762. Go to original source... Go to PubMed...
  3. George CD, Lee T, Hollestein LM, et al. Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis. Br J Dermatol. 2024 Mar 15;190(4):465-476. doi: 10.1093/bjd/ljad371. PMID: 37890083. Go to original source... Go to PubMed...
  4. Kandolf L, Peris K, Malvehy J, et al. European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes). J Eur Acad Dermatol Venereol. 2024 Jun;38(6):1024-1047. doi: 10.1111/jdv.19897. Epub 2024 Mar 7. PMID: 38451047. Go to original source... Go to PubMed...
  5. Vingan NR, Panton JA, Barillas J, et al. Investigating the efficacy of a fractionated 1927 nm laser for diffuse dyspigmentation and actinic changes. Lasers Surg Med. 2023;55:344-358. https://doi.org/10.1002/lsm.23653. Go to original source... Go to PubMed...
  6. Weiss ET, Brauer JA, Anolik R, et al. 1927-nm Fractional resurfacing of facial actinic keratoses: A promising new therapeutic option. J Am Acad Dermatol. 2012. doi:10.1016/j.jaad.2012.05.033. Go to original source...
  7. Arisi M, Guasco Pisani E, Calzavara-Pinton P, et al. Cryotherapy for Actinic Keratosis: Basic Principles and Literature Review. Clin Cosmet Investig Dermatol. 2022 Mar 5;15:357-365. doi: 10.2147/CCID.S267190. PMID: 35283641; PMCID: PMC8906699. Go to original source... Go to PubMed...
  8. Singh R, McCain S, Feldman SR. Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis. JMIR Dermatol. 2023 Feb 15;6:e39988. doi: 10.2196/39988. PMID: 37632916; PMCID: PMC10335144. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.